Statement of Changes in Beneficial Ownership (4)
June 19 2020 - 5:36PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Svennilson Peter |
2. Issuer Name and Ticker or Trading Symbol
RAPT Therapeutics, Inc.
[
RAPT
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
|
|
(Last)
(First)
(Middle)
1700 OWENS STREET, SUITE 500 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
6/18/2020 |
|
(Street)
SAN FRANCISCO, CA 94158
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (right to buy) | $28.27 | 6/18/2020 | | A | | 22500 | | (1) | 6/17/2030 | Common Stock | 22500 | $0.00 | 22500 | D (2) | |
| Explanation of Responses: |
| (1) | The Option shall vest in a series of three successive equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's continuous service through each applicable vesting date. |
| (2) | The Reporting Person is a managing partner of The Column Group II GP, LP, Ponoi Management, LLC and Ponoi II Management, LLC which are the general partners of The Column Group II, LP ("TCG II LP"), Ponoi Capital, LP ("Ponoi LP") and Ponoi Capital II, LP ("Ponoi II LP"), respectively. Under the partnership agreements of TCG II LP, Ponoi LP and Ponoi II LP (collectively, the "Funds"), the Reporting Person is deemed to hold the Option for the economic benefit of the Funds. The Funds and their respective general partners may be deemed indirect beneficial owners of the Option and the Reporting Person may be deemed the indirect beneficial owner of the Option through his indirect interest in the Funds. The Reporting Person disclaims beneficial ownership of the Option except to the extent of his pecuniary interest therein. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Svennilson Peter
1700 OWENS STREET
SUITE 500
SAN FRANCISCO, CA 94158 | X | X |
|
|
Signatures
|
| /s/ Jennifer J. Carlson, Attorney-in-Fact | | 6/19/2020 |
| **Signature of Reporting Person | Date |
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Apr 2023 to Apr 2024
